2024-516477-73-00招募中1 期
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Exelixis Inc.6 个研究点 分布在 2 个国家目标入组 320 人开始时间: 2024年9月16日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 320
- 试验地点
- 6
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Exelixis, Inc.
Scientific
Exelixis Inc.
研究点 (6)
Loading locations...
相似试验
已完成
不适用
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid TumorsNL-OMON50370Exelixis, Inc25
进行中（未招募）
1 期
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsUrothelial CarcinomaCastration-resistant Prostate CancerTriple Negative Breast CancerEndometrial CancerGastroesophageal Junction AdenocarcinomaColorectal CancerOvarian CancerGastric CancerHead and Neck CancerDifferentiated Thyroid CancerLower Esophageal CancerRenal Cell CarcinomaHepatocellular CarcinomaNon-Small Cell Lung CancerNCT03170960Exelixis914
进行中（未招募）
1 期
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.CTIS2024-511292-15-00Grupo Espanol De Tumores Neuroendocrinos41
招募中
1 期
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerNCT05613894University of Utah33
进行中（未招募）
1 期
Study of cabozantinib in metastatic renal carcinoma in aged fragile patientsEUCTR2019-001639-30-ESSpanish Oncology Genitourinary Group - SOGUG50